TRAMETINIB EXPERIENCE IN A BRAF P.N 486 _P490DEL MUTATION POSITIVE LANGERHANS CELL HISTIOCYTOSIS

Gencel Karaaslan, Sevim; Erkol Tuncer, Gül Hatice; Yaman Ortakoylu, Melek; Incesoy Ozdemir, Sonay; Dincaslan, Handan; Tacyildiz, Nurdan; Fitoz, Ömer Suat; Ceyhan, Koray; Kuzu, Isinsu; Cabi Unal, Emel

doi:10.1016/j.htct.2022.09.1273

Hematology, Transfusion and Cell Therapy

ISSN: 2531-1379

Hematology, Transfusion and Cell Therapy is a quarterly scientific publication of the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), Associazione Italo-Brasiliana di Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG), and Sociedade Brasileira de Oncologia Pediátrica (SOBOPE).

Hematology, Transfusion and Cell Therapy publishes original articles, review articles and case reports covering various areas in the field of hematology and hemotherapy. The journal was previously published, until 2016, as Revista Brasileira de Hematologia e Hemoterapia.

ISSN print: 2531-1379
ISSN online: 2531-1387

Published by Elsevier Editora Ltda, Rio de Janeiro, Brazil.

Consensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management.

Indexed in:

Web of Science, LILACS, SciELO Brazil, ESCI (Web of Science), Scopus, and PubMed/PMC

Case report In Langerhans cell histiocytosis thyroid involvement is rarely seen. Here, we would like to present a 12-year-old male patient with lung, external auditory canal skin and lymph node involvement in diagnosis. Disease relapse occurred with thyroid involvement 19 months after remission. In molecular analysis, BRAF p.N 486 _P490del was detected and he reccived MEK inhibitor Trametinib monotherapy. He is still in remission for 16 months.

Full text is only aviable in PDF

Indexed in:

Follow us:

Subscribe to our newsletter